ETNB logo

89bio (ETNB) Company Overview

Profile

Full Name:

89bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 11, 2019

Indexes:

Not included

Description:

ETNB (89bio) is a biotechnology company focused on developing innovative treatments for liver and metabolic diseases. They aim to improve patient outcomes through advanced therapies, leveraging their expertise in drug development and research to address unmet medical needs in these areas.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 4, 25 Wolfe Research
Outperform
Jan 31, 25 UBS
Buy
Jan 21, 25 HC Wainwright & Co.
Buy
Jan 2, 25 Cantor Fitzgerald
Overweight
Nov 11, 24 HC Wainwright & Co.
Buy
Nov 8, 24 Raymond James
Strong Buy
Sep 20, 24 Cantor Fitzgerald
Overweight
Aug 6, 24 Raymond James
Strong Buy
Aug 6, 24 RBC Capital
Sector Perform
Aug 6, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

89bio's Pegozafermin Is Now Gaining Momentum
89bio's Pegozafermin Is Now Gaining Momentum
89bio's Pegozafermin Is Now Gaining Momentum
ETNB
seekingalpha.comJanuary 30, 2025

89bio's Pegozafermin Is Now Gaining Momentum

Why 89bio Stock Lagged the Market Today
Why 89bio Stock Lagged the Market Today
Why 89bio Stock Lagged the Market Today
ETNB
Motley FoolJanuary 28, 2025

On Tuesday, 89bio (NASDAQ: ETNB) struggled to match the overall performance of the stock market. Investors were cautious about purchasing shares of the clinical-stage biotech company after it announced plans for a new stock offering. After the market closed on Monday, 89bio revealed its goal to raise up to $287.5 million through this secondary stock issue.

Why 89bio Stock Lagged the Market Today
Why 89bio Stock Lagged the Market Today
Why 89bio Stock Lagged the Market Today
ETNB
fool.comJanuary 28, 2025

89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue.

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
ETNB
globenewswire.comJanuary 27, 2025

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
ETNB
seekingalpha.comJanuary 13, 2025

89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 ENTRIGUE study indicated that patients treated with all doses of pegozafermin were able to achieve the primary endpoint with statistical significance. The global severe hypertriglyceridemia treatment market is expected to reach $2.67 billion by 2033.

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
ETNB
globenewswire.comNovember 15, 2024

New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
ETNB
globenewswire.comOctober 15, 2024

SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be featured in four poster presentations at the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2024 being held November 15 to 19, 2024 in San Diego, California.

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
ETNB
globenewswire.comSeptember 30, 2024

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
ETNB
globenewswire.comSeptember 16, 2024

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company.

89bio Appoints Francis Sarena as Chief Operating Officer
89bio Appoints Francis Sarena as Chief Operating Officer
89bio Appoints Francis Sarena as Chief Operating Officer
ETNB
globenewswire.comAugust 7, 2024

SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024.

FAQ

  • What is the ticker symbol for 89bio?
  • Does 89bio pay dividends?
  • What sector is 89bio in?
  • What industry is 89bio in?
  • What country is 89bio based in?
  • When did 89bio go public?
  • Is 89bio in the S&P 500?
  • Is 89bio in the NASDAQ 100?
  • Is 89bio in the Dow Jones?
  • When was 89bio's last earnings report?
  • When does 89bio report earnings?
  • Should I buy 89bio stock now?

What is the ticker symbol for 89bio?

The ticker symbol for 89bio is NASDAQ:ETNB

Does 89bio pay dividends?

No, 89bio does not pay dividends

What sector is 89bio in?

89bio is in the Healthcare sector

What industry is 89bio in?

89bio is in the Biotechnology industry

What country is 89bio based in?

89bio is headquartered in United States

When did 89bio go public?

89bio's initial public offering (IPO) was on November 11, 2019

Is 89bio in the S&P 500?

No, 89bio is not included in the S&P 500 index

Is 89bio in the NASDAQ 100?

No, 89bio is not included in the NASDAQ 100 index

Is 89bio in the Dow Jones?

No, 89bio is not included in the Dow Jones index

When was 89bio's last earnings report?

89bio's most recent earnings report was on Nov 7, 2024

When does 89bio report earnings?

The next expected earnings date for 89bio is Feb 28, 2025

Should I buy 89bio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions